Skip to main content

IntegriDerm Gets NIH Grant to Develop GI Tract Microarray


  IntegriDerm, the Huntsville, Ala., manufacturer of specialized DermArray, is going under the skin to develop a specialized gastrointestinal DNA array.

The development will be funded by a $147,650 National Institutes of Health Small Business Innovation Research Phase I grant the company was awarded last week.

In this project, the company will be using a proprietary computer-assisted approach it used to select the genes for its nylon-based DermArray, which includes 4,400 skin-disease related genes, and PharmArray, which includes genes relevant to drug targets, said Tom Dooley, CEO of IntegriDerm. The new array will sell for $1,580 per nylon membrane. Each membrane can be reused five times.

This new chip signals IntegriDerm’s strategy to capture specialized markets within the array sector. “A lot of other companies have broad strategies to screen as many genes as they can, but ours is to take a small niche area and stick with it,” said Dooley. “In the gastroenterology field there isn’t really a product on the market, and our objective is to capture the same kinds of clients we have with the dermatology array.”

The company has hired Ernest Curto, a gastroenterology specialist from the University of Alabama at Birmingham, as a principal investigator on the grant.


The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.